Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: Influence of gastrointestinal dysfunction on the relative bioavailability of two formulations

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 3, 2008, Pages 889-894

  Aghazadeh Habashi, Ali ^a   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Absorption; Analgesic; Bioavailability; Bioequivalence; Gastrointestinal dysfunction; NSAIDs; Onset; Pharmacokinetic

Indexed keywords

MELOXICAM; PROPANTHELINE BROMIDE;

ANIMAL EXPERIMENT; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSAGE FORM; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SECRETION; MALE; NONHUMAN; RAT; SIMULATION; STOMACH JUICE; TABLET FORMULATION; VAGUS NERVE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; GASTRIC JUICE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; INTESTINAL ABSORPTION; MUSCARINIC ANTAGONISTS; PILOT PROJECTS; PROPANTHELINE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TABLETS; THIAZINES; THIAZOLES; VAGUS NERVE;

EID: 54849442861     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.07.013     Document Type: Article

References (39)

1. Jamali F., and Kunz-Dober C.M. Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. Br. J. Clin. Pharmacol. 47 (1999) 391-396
2. Anonymous, Compendium of Pharmaceuticals and Specialties, (Eds.). Ottawa, ON, Canada: Canadian Pharmaceutical Association, 2003, 83-85.
3. Jamali F., and Aghazadeh-Habashi F.A. Rapidly dissolving formulations for quick absorption during pain episodes: ibuprofen. Int. J. Clin. Pharmacol. Ther. 46 2 (2008) 55-63
4. Aurora S.K., Kori S.H., Barrodale P., McDonald S.A., and Haseley D. Gastric stasis in migraine: more than just a proximal abnormality during a migraine attack. Headache 46 (2006) 57-63
5. Buckles D.C., Sarosiek I., Mc Millin C., and Mc Callum R.W. Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am. J. Med. Sci. 327 (2004) 1-4
6. Volans G.N. Migraine and drug absorption. Clin. Pharmacokinet. 3 (1978) 313-318
7. Laska E.M., Sunshine A., Marrero I., Olson N., Siegel C., and McCormick N. The correlation between blood levels of ibuprofen and clinical analgesic response. Clin. Pharmacol. Ther. 40 (1986) 1-7
8. Seymour R.A., Kelly P.J., and Hawkesford J.E. Pharmacokinetics and efficacy of low-dose ketoprofen in prospective dental pain. Clin. Drug Invest. 15 (1998) 279-284
9. Pariet M., vanRyn J., Schierok H., Mauz A., Trummlitz G., and Engelhardt G. Differential inhibition of cyclooxigenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm. Res. 47 6 (1998) 270-276
10. Distel M., Mueller C., and Fries J. Safety of meloxicam: a global analysis of clinical trails. Br. J. Rheumatol. 35 Suppl. 1 (1996) 68-77
11. Dequeker J., Hawkey C., Kahan A., Steinbruck A., Aleger C., Baumelou E., et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br. J. Rheumatol. 37 (1998) 946-951
12. Harirforoosh S., Aghazadeh-Habashi A., and Jamali F. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. Clin. Exp. Pharmacol. Physiol. 33 (2006) 917-924
13. Harirforoosh S., and Jamali F. Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam. J. Appl. Toxicol. 28 (2008) 829-838
14. Hawkey C., Kahan A., Steinbruck K., Alegre C., Baumelou E., Begaud B., et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br. J. Rheumatol. 37 (1998) 937-945
15. Huang W.F., Hsiao F.Y., Tsai Y.W., Wen Y.W., and Shih Y.T. Cardiovascular events associated with long-term use of celecoxib rofecoxib and meloxicam in Taiwan: an observational study. Drug Saf. 29 3 (2006) 261-272
16. Clavo A.M., Sakai V.T., Giglio F.P., Modena K.C., Colombini B.L., Benetello V., Sakamoto F.C., Freire T.M., Dionísio T.J., Lauris J.R., Trindade Jr. A.S., Faria F.A., and Santos C.F. Analgesic anti-inflammatory dose-response relationship of 7.5-15 mg meloxicam after lower third molar removal: a double-blind, randomized crossover study. Int. J. Oral Maxillofac. Surg. 36 1 (2007) 26-31
17. Ahmed M., Khanna D., and Furst D.E. Meloxicam in rheumatoid arthritis. Expert Opin. Drug Metab. Toxicol. 1 4 (2005) 739-751
18. Aoki T., Yamaguchi H., Naito H., Shiiki K., Izawa K., Ota Y., Sakamoto H., and Kaneko A. Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int. J. Oral Maxillofac. Surg. 35 7 (2006) 613-617
19. de Mello N.R., Baracat E.C., Tomaz G., Bedone A.J., Camargos A., Barbosa I.C., de Souza R.N., Rumi D.O., Alcala F.O.M., Velasco J.A.A., and Cortes R.J.R. Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet. Gynecol. Scand. 83 7 (2004) 667-673
20. Cheng T.T., Lai H.M., Chiu C.K., and Chem Y.C. A single-blind, Randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin. Ther. 26 3 (2004) 399-406
21. Luger P., Daneck K., Engel W., Trummlitz G., and Wagner K. Structure and physiochemical properties of meloxicam, a new NSAID. Eur. J. Pharm. Sci. 4 (1996) 175-187
22. Busch U., Schmid J., Heinzel G., Schmus H., Baierl J., Huber C., and Roth W. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab. Dispos. 26 6 (1998) 576-584
23. Aguilar-Mariscal H., Patino-Camacho S.I., Rodriguez-Silverio J., Torres-Lopez J.E., and Flores-Murrieta F.J. Oral pharmacokinetics of meloxicam in the rat using a high-performance liquid chromatography method in micro-whole-blood samples. Methods Find. Exp. Clin. Pharmacol. 29 9 (2007) 578-591
24. Han H.K., and Choi H.K. Improved absorption of meloxicam via salt formation with ethanolamines. Eur. J. Pharm. Biopharm. 65 (2007) 99-103
25. Turck D., Busch U., Heinzel G., and Narjes H. Clinical pharmacokinetics of meloxicam. Drug Res. 47 I (1997) 253-258
26. ®): pharmacokinetic in healthy female Mexican population, Biopharm. Drug Dispos. 26 (2005) 167-171
27. Davies N., and Skjodt N.M. Clinical pharmacokinetics of meloxicam. Clin. Pharmcokinet. 36 2 (1999) 115-126
28. Seedher N., and Bhatia S. Solubility enhancement of COX-2 inhibitors using various solvent, systems. AAPS PharmSciTech 4 3 (2003) 1-9
29. Ghorab M.M., Abdel-Salam H.M., El-Sayad M.A., and Mekhel M.M. Tablet formulation containing meloxicam and β-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS PharmSciTech 5 4 (2004) 1-6
30. Sharma S., Sher P., Badve S., and Pawar A.P. Adsorption of meloxicam on porous calcium silicate, Characterization and tablet formulation. AAPS PharmSciTech 6 4 (2005) E618-E625
31. Chiou W.L., Ma C., Chung S.M., Wu T.C., and Jeong H.Y. Similarity in the linear and non-linear oral absorption of drugs between human and rat. Int. J. Clin. Pharmacol. Ther. 38 (2000) 532-549 Erratum in: Int. J. Clin. Pharmacol. Ther. 39 (2001) 138
32. Zhao Y.H., Abraham M.H., Le J., Hersey A., Luscombe C.N., Beck G., Sherborne B., and Cooper I. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur. J. Med. Chem. 38 (2003) 233-243
33. Shaw L.R., Irwin W.J., Grattan T.J., and Conway B.R. The effect of selected water-soluble excipients on the dissolution of paracetamol and Ibuprofen. Drug Dev. Ind. Pharm. 31 (2005) 515-525
34. United States Pharmacopia, 28th ed., United State Pharmacopial Convention Inc., (2005) 2412-2414.
35. Velpandian T., Jaiswal J., Bhardwaj R.K., and Gupta S.K. Development and validation of a new high-performance liquid chromatographic estimation method of meloxicam in biological samples. J. Chromatogr. B738 (2000) 431-436
36. Anonymous, Guidance for Industry, Conduct and Analysis of Bioavailability and Bioequivalence Studies - Part A: Oral Dosage Formulations Used for Systemic Effects. Heath Products and Food Branch, Health Canada. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/draft_ebauche_ctdbe_e.pdf.
37. Busch U., Heinzel G., and Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam a new non-steroidal anti-inflammatory drug (NSAID), in man. Eur. J. Clin. Pharmacol. 48 (1995) 269-272
38. Evers S., Afra J., Frese A., Goadsby P.J., linde M., May A., and Sandor P.S. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur. J. Neurol. 13 (2006) 560-572
39. Houghton L.A., Fowler P., Keene O.N., and Read N.W. Effect of sumatriptan a new selective 5HT1like agonist on liquid gastric emptying in man. Aliment. Pharmacol. Ther. 6 (1992) 685-691